
Precision Medicine in Oncology®
Latest News
Advertisement
Latest Videos

CME Content
Advertisement
More News




Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of olaparib (Lynparza) for patients with BRCA-positive breast cancers and the impact it has had on clinical practice. Tripathy shared this insight in an interview during the 35th Annual Miami Breast Cancer Conference.





















Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Hematology Experts Preview Key Abstracts to Watch at the 2026 Transplantation & Cellular Therapy Meetings
3
Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types
4
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
5













































